Shire pipeline 'to add $3bn in sales by 2020'
This article was originally published in Scrip
Shire says drug candidates in its pipeline will contribute $3bn in sales by 2020. The company set out its wares at an R&D day in New York eight weeks after AbbVie pulled out of a $53bn offer for the rare disease specialist following the US Treasury's tightening of tax rules (scripintelligence.com, 16 October 2014).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.